Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
anastrozole (arimidex) (1 trial)
exemestane (aromasin) (2 trials)
fulvestrant (faslodex) (4 trials)
lapatinib (tykerb) (2 trials)
letrozole (femara) (9 trials)
paclitaxel (taxol) (9 trials)
palbociclib (ibrance) (4 trials)
pertuzumab (perjeta) (3 trials)
ribociclib (kisqali) (3 trials)
trastuzumab (herceptin) (9 trials)
atezolizumab (Tecentriq) (3 trials)
autologous tumor infiltrating lymphocytes (1 trial)
buparlisib (2 trials)
cyclophosphamide (cytoxan) (1 trial)
doxorubicin (Doxil) (3 trials)
durvalumab (imfinzi) (1 trial)
elacestrant (Orserdu) (2 trials)
enzalutamide (xtandi) (1 trial)
eribulin (halaven) (1 trial)
iniparib (1 trial)
ipatasertib (2 trials)
neratinib maleate (nerlynx) (1 trial)
olaparib (lynparza) (2 trials)
patritumab (1 trial)
pembrolizumab (keytruda) (2 trials)
spartalizumab (1 trial)
tamoxifen (nolvadex) (1 trial)
taselisib (1 trial)
triptorelin (Trelstar) (1 trial)
vinorelbine (navelbine) (2 trials)
onapristone (1 trial)
pelareorep (1 trial)
talimogene laherparepvec (Imlygic) (1 trial)
u3-1402 (1 trial)
Breast Neoplasms (Phase 3)
Heart Diseases (Phase 2)
Neoplasm, Residual (Phase 1)
Triple Negative Breast Neoplasms (Phase 2)
Trials (35 total)
Trial APIs (34 total)